Pesadin

Quick links to important sections

Pesadin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pesadin

What is Pesadin? Foundational Overview

Property Description
Active ingredient Dipyridamole (C24H40N8O4)
Form Tablets (Oral), Solution (Intravenous)
Pharmacological class Antiplatelet Agent, Vasodilator
General Purpose Supporting blood flow, preventing platelet clumping
Origin Synthetic Compound (Pyrimidopyrimidine Derivative)

Defining Pesadin: Composition and Pharmacological Classification

Pesadin is a medicinal preparation whose active ingredient is Dipyridamole, a synthetic compound derived from the pyrimidopyrimidine chemical structure. It is rigorously classified as both an antiplatelet agent and a vasodilator, a dual capacity that has been clinically recognized for decades. This classification establishes Dipyridamole’s functional distinction: it modulates platelet activity and promotes the widening of blood vessels. Its dual mechanism contrasts with agents focused solely on one aspect of the clotting process, which is why Dipyridamole is often utilized in medical settings to help maintain circulation and inhibit blood clotting.

What Forms is Dipyridamole Available In, and What is Its General Purpose?

Dipyridamole is manufactured for administration via two principal routes: as tablets for standard oral use and as an injection/solution for intravenous administration, which is typically reserved for specialized diagnostic procedures. The comprehensive therapeutic purpose of this antithrombotic agent is to ensure the consistent patency of blood vessels. It is characterized by its ability to help improve microcirculation, which is fundamental to maintaining healthy blood flow. This compound achieves its purpose by concurrently mitigating platelet activity and facilitating the relaxation of vascular walls, thereby supporting circulation where the risk of clot formation is a concern.

Regulatory References

  1. Dipyridamole - StatPearls - NCBI Bookshelf

What side effects are possible with Pesadin?

Possible Side Effects and Safety Information

The safety profile of Pesadin (Dipyridamole) is characterized by adverse reactions documented by regulatory authorities and classified by frequency and affected body system. The most frequently reported adverse effects often relate to the medicine's vasodilatory effects and are generally transient upon continued long-term use, as stated in official labeling.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by how often they are reported in regulatory documents:

Classification Examples of Reactions Affected Systems (SOC)
Very Common Headache, Diarrhea, Dyspepsia (Indigestion), Nausea Nervous System, Gastrointestinal
Common Dizziness, Vomiting, Rash, Angina Pectoris (Chest Pain) Nervous System, Gastrointestinal, Skin, Cardiac
Rare/Post-Marketing Hypersensitivity reactions (e.g., Bronchospasm), Thrombocytopenia, Hepatic failure Immune System, Hematologic, Hepatobiliary

Serious Adverse Reactions and Safety Constraints

Official labeling documents an increased risk of hemorrhage, including severe events such as Intracranial Hemorrhage, consistent with the drug's antiplatelet action. Reports of Hepatic Failure and significant elevations of hepatic enzymes are also part of the documented safety profile.

Regulatory safety constraints advise caution in specific patient groups. Use is generally recommended to be avoided in individuals with severe hepatic or renal insufficiency. Caution is also advised when administering to patients with severe coronary artery disease due to the potential for the medicine's vasodilatory effect to aggravate existing conditions.

Overdose and Emergency Response

This section details the officially documented signs and required emergency actions for an overdose of Pesadin, based on government regulatory information.

Documented Overdose Manifestations The official regulatory profile for Pesadin overdose details symptoms indicative of excessive vasodilation. Documented presentations include feeling warm, flushing, sweating, restlessness, feeling of weakness, and dizziness. There is also a risk of the aggravation of existing angina complaints. Severe outcomes are strictly defined by acute hemodynamic effects: a significant drop in blood pressure (hypotension) and an abnormally rapid heart rate (tachycardia).

Required Emergency Response Immediate medical attention is required for any suspected overdose. Emergency services must be contacted immediately for life-threatening symptoms such as collapse, seizure, trouble breathing, or inability to awaken. Regulatory management protocols advise ECG monitoring and the provision of symptomatic and supportive treatment. The label specifies that the administration of xanthine derivatives, such as aminophylline, may be used to reverse the documented hemodynamic effects. Due to its distribution and hepatic elimination, Pesadin is not accessible to enhanced removal procedures like dialysis. This profile dictates a swift and focused medical response.

Therapeutic Uses of Pesadin

What Pesadin Treats: Main Uses and Benefits

Pesadin is commonly used to help with the conditions that may occur when blood flow is compromised by blood clots. This use is relevant across therapeutic domains where additional support against the formation of dangerous clots is needed.

The medication supports the management of conditions marked by a high risk of recurrent vascular events, such as secondary stroke and Transient Ischemic Attack (TIA), and is used for supportive management following mechanical heart valve replacement. Its core benefit is to provide supportive protection against thromboembolic complications.

“This medication is primarily relevant for individuals facing elevated risks of blood clot formation due to pre-existing vascular concerns or the presence of a mechanical heart device.”

Pesadin supports the patient by assisting with maintaining functional stability and contributing to the easing of the overall symptom load related to conditions involving compromised circulation.


Quick Fact: Support for Vascular Risk Management

The drug plays a role in managing symptomatic risk by contributing to the support of blood flow and helping patients cope more steadily with symptom fluctuations associated with high-risk vascular conditions.

Regulatory References

  1. Dipyridamole: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Pesadin? (Dipyridamole) — Official Regulatory Information

Pesadin eligibility is strictly defined by government regulatory documents, focusing on absolute contraindications and population-specific restrictions.

Eligibility Scope

Category Regulatory Status/Rule
Populations for whom use is allowed Adults requiring antiplatelet therapy for licensed indications.
Populations for whom use is contraindicated Patients with known hypersensitivity to dipyridamole or any product component.
Age-related eligibility rules Pediatric Use is not established below 12 years of age. Older adults may require special consideration or caution.
Condition-specific eligibility rules Use must be avoided in patients with severe hepatic insufficiency (liver failure) and severe renal failure (GFR less than 10 mL/minute).
Pregnancy and lactation eligibility status Pregnancy: Use is conditional, only if clearly needed. Lactation: Caution is advised as the drug is excreted into human milk.
Eligibility-related restrictions Use requires caution in patients with certain conditions, including severe coronary artery disease (e.g., unstable angina) and hypotension (low blood pressure).

Connection to the overall eligibility profile

Official regulatory documents establish who can use Pesadin by setting strict constraints based on patient characteristics and pre-existing health conditions. These rules include absolute prohibition for allergic individuals and avoidance or conditional use status for those with organ impairment, specific heart conditions, and age groups where safety data is not fully established.

What should I know about interactions with other medicines?

The official regulatory profile for Pesadin (Dipyridamole) documents interactions based on pharmacodynamic reinforcement and transporter-mediated exposure modification.

Contraindicated and Restricted Combinations

Co-administration with the guanylate cyclase stimulator Riociguat is prohibited due to the risk of additive hypotension. The combination with Abrocitinib is also strictly restricted during the initial treatment period because of the documented increase in the risk of bleeding and thrombocytopenia.

Documented Interaction Patterns

Co-administration with other antiplatelet agents or anticoagulants is documented to increase the overall risk of hemorrhage. The drug has been reported to increase the plasma exposure and cardiovascular effects of Adenosinergic agents used in diagnostic testing. This exposure alteration is partly due to Dipyridamole's known activity as an inhibitor of the P-glycoprotein (P-gp) and BCRP efflux transporters, which can lead to increased concentrations of certain co-administered substrate medicines.

Timing and Procedural Rules

Specific timing constraints are mandated for diagnostic use. Oral Pesadin must be held for 48 hours prior to intravenous adenosinergic agent administration, and methylxanthines must be discontinued for 12 to 24 hours to ensure test validity. Additionally, the drug may counteract the effect of cholinesterase inhibitors, with official regulatory caution noted for patients with Myasthenia Gravis.

Mechanism of Action

Pesadin targets two core molecular mechanisms to modulate platelet activity. It inhibits Phosphodiesterase (PDE) enzymes within platelets, thereby preventing the breakdown of the signaling molecule cAMP. The sustained high levels of cAMP maintains the platelet in a less reactive state, resulting in a reduction of its response to aggregating signals.

The drug also acts by blocking the Equilibrative Nucleoside Transporter 1 (ENT1), which is responsible for the reuptake of adenosine (a naturally occurring vasoactive and antiplatelet mediator) into cells. By blocking this reuptake, Pesadin increases the concentration of adenosine outside the cells, which enhances its action on vascular smooth muscle relaxation and platelet activity.

The accumulation of cAMP and cGMP in vascular smooth muscle cells leads to their relaxation, resulting in the physiological change of vessel widening (vasodilation). However, this non-selective mechanism can lead to the "coronary steal phenomenon" in certain vascular states, where blood flow is preferentially directed away from maximally dilated regions.

Dosage and Administration Information

How to Use Pesadin: Official Administration Guidelines

Pesadin, which contains the active ingredient Dipyridamole, is administered through two officially approved routes: the oral route for long-term supportive therapy and the intravenous (IV) infusion route for specialized diagnostic procedures. The specific usage pattern depends entirely on the purpose, which determines the dosage form and frequency.


Oral Regimens and Timing

For oral use as an adjunct to anticoagulation, such as for thromboembolism prophylaxis after cardiac valve replacement, the dose is often 75 mg to 100 mg administered four times a day. Immediate-release tablets are generally taken before meals (e.g., at least one hour before or two hours after) with a full glass of water. In contrast, the prolonged-release capsules (e.g., 200 mg) are typically taken twice daily and should be swallowed whole without crushing or chewing.


Intravenous and Population Use Constraints

The IV infusion is a single, short-term administration used in diagnostic procedures. It is administered over a fixed period of four minutes at a rate of 0.142 mg/kg/minute, with the total dose usually not exceeding 60 mg. The solution must be diluted immediately prior to use and should not be mixed with any other medication in the same container. Regarding population-specific instructions, official labeling for certain oral forms specifies no dosage adjustment for patients with renal or hepatic impairment. However, use in the pediatric population is generally not established for all indications.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Pesadin

Evidence for Secondary Prevention of Recurrent Stroke or TIA

Pesadin was studied for its role in research exploring the prevention of a second stroke or a transient ischemic attack (TIA). This research focused on individuals in patients with conditions characterized by fluctuating or episodic manifestations related to compromised blood flow.

The available research is primarily derived from large-scale, controlled clinical trials, known as Randomized Controlled Trials (RCTs), and systematic reviews. Researchers examined patients taking Pesadin (Dipyridamole) alone, aspirin alone, or a combination of both agents, comparing the outcomes monitored in these studies. The primary outcomes monitored were the occurrence of a recurrent stroke, heart attack (MI), and vascular death.

The findings describe patterns related to the monitored stroke outcomes when the combination of extended-release Pesadin and aspirin was observed in studies. However, some studies reported no clear difference in the measurements of vascular death when comparing the combination to aspirin alone. Studies also explored Pesadin as a single agent; however, findings were mixed when compared to aspirin alone, and evidence remains limited in some analyses.

Evidence for Supportive Management with Mechanical Heart Valves

The second major area of research examined Pesadin in studies following mechanical heart valve replacement. Individuals with these devices were also monitored on standard anti-clotting medication. Research examined Pesadin as an additional agent, or adjunct, to standard oral anticoagulant therapy (like warfarin).

The studies in this context monitored outcomes related to systemic or functional imbalance, primarily monitoring the incidence and frequency of severe thromboembolic events (blood clots that cause blockages). Early meta-analyses of randomized trials reported measurements related to the occurrence of these thromboembolic events and overall mortality when Pesadin was associated with oral anticoagulants compared to the anticoagulant used alone. Studies contribute to the broader evidence landscape regarding long-term monitoring of outcomes after these procedures.

Frequently Asked Questions (FAQ)

Common questions about Pesadin (FAQ)

Q: How quickly should I expect Pesadin to start working?

Studies describe that the active ingredient, dipyridamole, modulates platelet activity after administration. When taken by mouth, the concentration of the drug typically reaches its highest level in the bloodstream within about two to two and a half hours, according to official pharmacokinetic data.


Q: What types of food or drinks should be avoided while taking Pesadin?

Official documentation advises caution with products containing methylxanthines, a class that includes caffeine. This caution is associated with the potential for methylxanthines to affect the intended action of the drug, particularly during specific diagnostic tests. If you are undergoing such a procedure, the official guidance may mandate avoiding high caffeine intake for a period beforehand.


Q: How does Pesadin interact with common vitamins or supplements?

Regulatory documents describe that the drug may alter the body’s processing of other substances that are eliminated through specific cellular transporters, such as P-gp and BCRP. While official interaction lists do not specify every common vitamin or supplement, information regarding all co-administered substances, including supplements, should be shared with a healthcare provider for professional review.


Q: What is the general duration of treatment with Pesadin?

The oral formulation of Pesadin is typically described in official regulatory labels as being used for long-term supportive therapy. This refers to its function as an additional agent (adjunct) to standard anticoagulant therapy to help modulate blood clotting over an extended period.


Q: If I am taking blood pressure medicine, is it safe to use Pesadin?

Official information documents that Pesadin can cause blood vessels to widen (vasodilation), which may increase the risk of hypotension (low blood pressure) when it is co-administered with certain blood pressure-lowering agents. This is why caution is noted in official documents for patients with pre-existing hypotension (low blood pressure).


Q: How long does Pesadin typically stay in your system after stopping use?

Studies show that dipyridamole has a terminal half-life of approximately 11.6 hours. For procedural purposes, the official guidance explicitly requires the oral form to be stopped for 48 hours prior to specific diagnostic tests to ensure the validity and accuracy of the procedure.


Q: Does Pesadin interact with herbal remedies like St. John's Wort?

General regulatory guidance notes that certain herbal preparations, like St. John's Wort, can influence how the body processes medications by affecting liver enzymes. If Dipyridamole relies on these enzymes for processing, its intended action could be theoretically altered, as noted in general regulatory guidance.


Q: If I have a history of liver issues, can I still be prescribed Pesadin?

Official regulatory documents state that the use of Pesadin must be avoided in patients with severe hepatic insufficiency (advanced liver failure). Official information suggests that use in individuals with less severe hepatic issues may require careful professional consideration.


Q: How does the effectiveness of Pesadin compare to official expectations?

The official regulatory description of the drug is derived from the results documented in clinical studies for its approved uses. Labeling summarizes the patterns observed in research, such as the findings related to monitoring recurrent stroke and blood clot outcomes when the medicine is used in combination with aspirin.


Q: What information is available about Pesadin's use in children and adolescents?

Official regulatory documents state that the use of Pesadin is not established for patients below 12 years of age. For individuals 12 and older, use is subject to professional determination, as with all patients.


Q: What is the difference between Pesadin and other similar drugs people mention?

Official regulatory classifications define the active ingredient in Pesadin as both an antiplatelet agent and a vasodilator. Its dual mechanism involves inhibiting the PDE enzyme and blocking the reuptake of adenosine, which helps distinguish its functional role from drugs that focus solely on one anti-clotting or vascular action.


Q: Can Pesadin affect my ability to drive or operate machinery?

Official safety documents list potential side effects such as dizziness and hypotension (low blood pressure). Since these effects may affect a person's level of alertness or coordination, official guidance notes that caution should be exercised if these effects occur.


Q: Does Pesadin cause drowsiness or make you feel tired?

Official post-marketing experience reports include instances of fatigue and a general feeling of discomfort or weakness (malaise). Regulatory documents have also reported somnolence (drowsiness) as a rare side effect in clinical trial data for some forms of the medication.


Q: What should I do if I notice a change in mood while taking Pesadin?

Official side effect classifications list symptoms such as nervousness/anxiety as an uncommon reaction. A change in health status, such as a change in mood, is information that should be shared with a healthcare provider for their review.


Q: Is there a generic version of Pesadin available?

Yes, the active ingredient in Pesadin, which is Dipyridamole, is available in generic versions. These are recognized and listed in the FDA’s database of approved drug products.


Q: Does taking Pesadin at a specific time of day matter?

Official regulatory guidance often emphasizes taking oral medications, particularly the combined forms of Dipyridamole, at the same times each day. This is done to help maintain a stable and consistent level of the drug in the body over the course of the day.


Q: What's the difference between the immediate-release and extended-release forms of Pesadin?

Official labeling clarifies the difference based on their administration: the immediate-release (IR) tablet is typically taken four times a day. In contrast, the prolonged-release (ER) capsule is taken twice a day and is designed to release the medication slowly, meaning it must be swallowed whole.


Q: Can Pesadin affect the results of lab tests?

Yes, official information explicitly states that oral Pesadin must be discontinued for 48 hours prior to specific diagnostic tests, such as those that use adenosinergic agents. This instruction is mandated to ensure test validity and prevent impaired sensitivity of the diagnostic procedure.


Q: Are there specific patient groups that researchers focus on when studying Pesadin?

The research evidence cited in official documents focuses primarily on two main patient groups: individuals who have undergone mechanical heart valve replacement and patients who have experienced a recurrent stroke or transient ischemic attack (TIA).


Q: Does smoking affect how Pesadin works in the body?

General regulatory guidance notes that tobacco smoke may affect drug metabolism by inducing certain liver enzymes. If Dipyridamole relies on these enzymes for processing, its intended action may be theoretically altered.


Q: What should be done if I experience blurred vision while taking Pesadin?

Official documents list vision abnormalities as an uncommon side effect. Experiencing blurred vision represents a change in health status; this information should be documented and shared with a healthcare provider for their review.

How should Pesadin be stored and disposed of?

How to Store and Dispose of Pesadin

Pesadin (dipyridamole tablets) must be stored at controlled room temperature, defined as 68 F to 77 F (20 C to 25 C). The medication must be kept in its original, tightly closed container and stored away from excess heat, moisture, and direct light. It is prohibited to store the tablets in humid areas like a bathroom, and the product must be protected from freezing.

Child Safety and Disposal

The medicine must be stored out of the reach and sight of children and pets.

Disposal of unused or expired Pesadin should be conducted using a drug take-back program or authorized collection site. If these are unavailable, official guidance requires mixing the medicine with an undesirable substance (e.g., dirt) in a sealed bag and discarding it in the household trash; the tablets must not be crushed. The product must not be flushed down the toilet or poured into a drain unless specifically instructed by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pesadin found in:

A-Z Index: